Researcher
Tom Decroo
Affiliations
- HIV and Tuberculosis (Research unit)
Member
From1 Oct 2021 → Today - Sexual Health including HIV (Research unit)
Member
From13 Oct 2015 → 29 Jun 2017 - HIV and Tuberculosis (Research unit)
Member
From1 Jul 2013 → 30 Sep 2021
Projects
1 - 10 of 13
- Drug resistant tuberculosis: optimize the composition of new treatment regimens in VietnamFrom1 Jan 2023 → Today
- Impact of diagnostic delays and short treatment regimens on outcomes of rifampicin-resistant tuberculosis patients in CameroonFrom1 Jan 2022 → Today
- TB/NTM Research ClusterFrom1 Jan 2022 → Today
- Nontuberculous mycobacteria pulmonary disease and tuberculosis-nontuberculous mycobacteria co-infection: Epidemiology, diagnosis, and management at a tertiary health facility in GhanaFrom1 Jan 2022 → Today
- Alternative methodological approaches to assess longterm HIV virological and clinical outcomes in resource limited settingsFrom27 Apr 2021 → Today
- Performance of community-based ART programmes for key populations in Nigeria and sub-Saharan AfricaFrom1 Jan 2021 → Today
- Accurate diagnosis and effective treatment for tuberculosis retreatment patients in NigerFrom1 Jan 2021 → Today
- Innovative diagnostic and therapeutic measures to improve MDR-TB diagnosis and management in Conakry, GuineaFrom1 Jan 2020 → Today
- Novel High-Dose Tuberculosis Retreatment Regimens: How to overcome resistance without creating more?From1 Oct 2018 → Today
- Novel high-dose tuberclosis retreatment regimens: How to overcome resistance without creating more?From1 Oct 2018 → 30 Sep 2021
Publications
41 - 50 of 128
- Thin-layer-agar-based direct phenotypic drug susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance otherwise missed by WHO-endorsed diagnostic tests(2021)
Authors: Elisa Ardizzoni, E. Ariza, D. Mulengwa, Q. Mpala, R de la Tour, Gugu Maphalala, F. Varaine, Bernhard Kerschberger, Pieter Graulus, A-L Page, et al.
- Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?(2021)
Authors: Sabira Tahseen, Armand Van Deun, Bouke de Jong, T Decroo
Pages: 831-835 - Finding the right balance between efficacy and tolerability for TB treatment: the search continues(2021)
Authors: A.K.J. Maug, M.A. Hossain, M Gumusboga, T Decroo, W Mulders, Sofie Braet, Jozefien Buyze, D A Jiménez, Céline Schurmans, Natacha Herssens, et al.
Pages: 84-86 - Should treatment of low-level rifampicin mono-resistant tuberculosis be different?(2021)
Authors: Armand Van Deun, Tom Decroo
- "I don't know when he will be back": life-changing events challenge the community ART Group model- a qualitative research study, Tete, Mozambique(2021)
Authors: Ivan Alejandro Pulido Tarquino, Emilie Venables, Raja Reis Simone, Jose Manuel de Amaral Fidelis, Tom Decroo
Pages: 1-9 - Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown(2021)
Authors: Armand Van Deun, T Decroo, Kya Jai Maug Aung, Mohamed Anwar Hossain, M Gumusboga, P De Rijk, Sabira Tahseen, Bouke de Jong, Leen Rigouts
- Community health worker-led ART delivery improved scheduled antiretroviral drug refill among men who have sex with men in Lagos State, Nigeria(2021)
Authors: Olujuwon Justin Ibiloye, Patrick Akande, Jwanle Plang, Franklin Emerenini, Temiwoluwa Omole, Olusola Osindero, Tom Decroo
Pages: 196-198 - Predictors of rifampicin-resistant tuberculosis mortality among HIV-coinfected patients in Rwanda(2021)
Authors: Dominique Savio Habimana, Jean Claude Semuto Ngabonziza, Patrick Migambi, Yves Mucyo Habimana, Grace Mutembayire, Francine Byukusenge, Innocent Habiyambere, Eric Remera, Placidie Mugwaneza, Ivan Emil Mwikarago, et al.
Pages: 47-53 - High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss(2021)
Authors: Mahamadou Bassirou Souleymane, Alberto Piubello, Ibrahim Mamane Lawan, Souleymane Hassane-Harouna, Mourtala Mohamed Assao-Neino, Alphazazi Soumana, Zelika Hamidou-Harouna, Assiatou Gagara-Issoufou, Nimer Ortuno-Gutierrez, Alberto Roggi, et al.
- Low cycle threshold value in Xpert MTB/RIF assay may herald false detection of tuberculosis and rifampicin resistance: a study of two cases(2021)
Authors: Jean Claude Semuto Ngabonziza, T Decroo, Rodrigue Maniliho, Yves Mucyo Habimana, Armand Van Deun, Bouke de Jong